Related Experiment Video
Updated: Jul 8, 2026
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Integrating genetic approaches into the discovery of anticancer drugs
L H Hartwell1, P Szankasi, C J Roberts
1Seattle Project, Molecular Pharmacology Department, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Abstract:
The discovery of anticancer drugs is now driven by the numerous molecular alterations identified in tumor cells over the past decade. To exploit these alterations, it is necessary to understand how they define a molecular context that allows increased sensitivity to particular compounds. Traditional genetic approaches together with the new wealth of genomic information for both human and model organisms open up strategies by which drugs can be profiled for their ability to selectively kill cells in a molecular context that matches those found in tumors. Similarly, it may be possible to identify and validate new targets for drugs that would selectively kill tumor cells with a particular molecular context. This article outlines some of the ways that yeast genetics can be used to streamline anticancer drug discovery.
Insights
Yeast genetics can streamline anticancer drug discovery by profiling compounds against specific tumor molecular contexts. This approach aids in identifying novel drug targets and validating existing ones for selective cancer cell killing.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Anticancer drug discovery increasingly relies on understanding molecular alterations in tumor cells.
- Identifying specific molecular contexts that confer sensitivity to anticancer drugs is crucial.
- Genomic data from humans and model organisms offer new strategies for drug development.
Purpose of the Study:
- To outline how yeast genetics can be applied to anticancer drug discovery.
- To explore strategies for profiling anticancer drugs based on tumor molecular contexts.
- To identify and validate new drug targets for selective cancer cell elimination.
Main Methods:
- Utilizing traditional genetic approaches in yeast.
- Leveraging extensive genomic information from human and model organisms.
- Profiling drug sensitivity in yeast models mimicking tumor molecular contexts.
Main Results:
- Yeast genetics provides a streamlined platform for anticancer drug discovery.
- The approach facilitates the identification of compounds selectively targeting tumor cells.
- It enables the validation of novel therapeutic targets based on specific molecular profiles.
Conclusions:
- Yeast genetics offers a powerful and efficient tool for advancing anticancer drug discovery.
- Understanding molecular context is key to developing targeted cancer therapies.
- This methodology can accelerate the identification and validation of effective anticancer agents.
Related Concept Videos
02:46Genetic Screens
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:26Drug Discovery: Overview
01:29Pharmacogenetics and Pharmacogenomics: Overview
01:29Pharmacogenomics: Identification of New Drug Targets